ALX Oncology: Funding, Investors & Team (Sep 2026)
ALX Oncology is a biotech company focused on creating groundbreaking cancer immunotherapy treatments. It operates as its own entity and is privately owned. The company was established based on groundbreaking technology created by Aaron Ring, K. Christopher Garcia, Kipp Weiskopf, Aron Levin, and Irving Weissman at Stanford University. This technology involves modified forms of signal regulatory protein-α (SIRPα) that have been engineered to bind CD47 with much higher affinity than naturally occurring SIRPα.
ALX Oncology has raised $178M across 3 funding rounds on record, the most recent an undisclosed round of $10.0M announced in Jun 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
ALX Oncology Company Profile and Key Stats
Latest funding round on record: Jun 2026.
ALX Oncology Funding Rounds
ALX Oncology raised $105M in an undisclosed round announced in Feb 2020.
3.7 years later, an undisclosed round of $63.2M was announced in Oct 2023.
2.7 years later, an undisclosed round of $10.0M was announced in Jun 2026.
ALX Oncology Founders and Leadership Team
Contact details for the ALX Oncology team: 2 of 2 have an email address on file.
Start 14-day free trial →ALX Oncology Funding Compared to Other Biotechnology Startups
ALX Oncology's latest round of $10.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ALX Oncology in Biotechnology and San Francisco
Companies Similar to ALX Oncology
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
ALX Oncology Funding FAQs
What does ALX Oncology do?
ALX Oncology is a biotech company focused on creating groundbreaking cancer immunotherapy treatments. It operates as its own entity and is privately owned. The company was established based on groundbreaking technology created by Aaron Ring, K. Christopher Garcia, Kipp Weiskopf, Aron Levin, and Irving Weissman at Stanford University. This technology involves modified forms of signal regulatory protein-α (SIRPα) that have been engineered to bind CD47 with much higher affinity than naturally occurring SIRPα.
How much funding has ALX Oncology raised?
ALX Oncology has raised $178M across 3 rounds on record. The most recent is an undisclosed round of $10.0M announced in Jun 2026.
When did ALX Oncology last raise funding?
ALX Oncology's most recent funding round on record is an undisclosed round of $10.0M, announced in Jun 2026.
Who founded ALX Oncology?
FundedIQ lists Jason Lettmann (Founder) at ALX Oncology.
Who is the CEO of ALX Oncology?
Jaume Pons is listed as CEO at ALX Oncology.
Where is ALX Oncology headquartered?
ALX Oncology is based in San Francisco, California, United States.
How many employees does ALX Oncology have?
ALX Oncology is in the 51-100 employee band.
How does ALX Oncology's funding compare to other Biotechnology startups?
ALX Oncology's latest round of $10.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's ALX Oncology Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ALX Oncology is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.